Evidence map›Paper›PMID 30221475›Full record

ArticleMolecular oncology2018

Oncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer.

Stephanie S Liu, Karen K L Chan, Daniel K H Chu, Tina N Wei, Lesley S K Lau, Siew F Ngu, Mandy M Y Chu, Ka Yu Tse, Philip P C Ip, Enders K O Ng and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Stephanie S LiuDepartment of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, SAR, China.
Karen K L ChanDepartment of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, SAR, China.
Daniel K H ChuDepartment of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, SAR, China.
Tina N WeiDepartment of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, SAR, China.
Lesley S K LauDepartment of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, SAR, China.
Siew F NguDepartment of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, SAR, China.
Mandy M Y ChuDepartment of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, SAR, China.
Ka Yu TseDepartment of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, SAR, China.
Philip P C IpDepartment of Pathology, LKS Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, SAR, China.
Enders K O NgPangenia Lifesciences Limited, Billion Centre, Hong Kong, SAR, China.
Annie N Y CheungDepartment of Pathology, LKS Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, SAR, China.
Hextan Y S NganDepartment of Obstetrics & Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, SAR, China.
University of Hong Kong · HKChinese University of Hong Kong · CNQueen Mary Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is one of the leading causes of cancer death in women globally, despite the widespread use of cytology/human papillomavirus (HPV) screening. In the present study, we aimed to identify the potential role of microRNA (miRNA) as a diagnostic biomarker in the detection of cervical pre-malignant lesions and cancer. In total, we recruited 582 patients with cervical diseases and 145 control individuals. The expression levels of six miRNAs (miR-20a, miR-92a, miR-141, miR-183*, miR-210 and miR-944) were found to be significantly up-regulated in cervical cancer and pre-malignant lesions compared to normal cervical samples, indicating that they are oncogenic miRNAs. Receiver operating characteristic curve analysis showed that these six miRNAs can be used to distinguish patients with cervical pre-malignant lesions or cancer from normal individuals and they also had a good predictive performance, particularly in cervical lesions. Combined use of these six miRNAs further enhanced the diagnostic accuracy over any single miRNA marker, with an area under the curve of 0.998, 0.996 and 0.959, a diagnostic sensitivity of 97.9%, 97.2% and 91.4%, and a specificity of 98.6%, 96.6% and 87.6% for low-grade lesions, high-grade lesions and cancer, respectively. This six oncogenic miRNA signature may be suitable for use as diagnostic marker for cervical pre-malignant lesions and cancer in the near future.

Indexed as

Early Detection of CancerTranscriptomeAdultAgedAged, 80 and overCase-Control StudiesFemaleGene Expression Regulation, NeoplasticHumansMicroRNAsMiddle AgedRetrospective StudiesUterine Cervical DysplasiaUterine Cervical NeoplasmsMicroRNAscervical cancercervical intraepithelial neoplasiadiagnostic biomarkerhuman papillomavirusmicroRNAsensitivity and specificity

Identifiers

PMID30221475
PMCPMC6275249
OpenAlexW2890133068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.